Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price hit a new 52-week low on Wednesday . The company traded as low as $8.25 and last traded at $8.47, with a volume of 13081936 shares traded. The stock had previously closed at $9.08.

TEVA has been the topic of a number of research reports. Citigroup lowered their target price on Teva Pharmaceutical Industries from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, April 11th. UBS Group initiated coverage on Teva Pharmaceutical Industries in a research report on Thursday, March 7th. They set a “buy” rating and a $22.00 target price on the stock. Morgan Stanley lowered Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 target price on the stock. in a research report on Wednesday, March 6th. Zacks Investment Research raised Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 20th. Finally, SunTrust Banks initiated coverage on Teva Pharmaceutical Industries in a research report on Tuesday, March 19th. They set a “hold” rating and a $17.00 target price on the stock. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $17.81.

The firm has a market capitalization of $9.42 billion, a PE ratio of 3.06, a price-to-earnings-growth ratio of 1.12 and a beta of 1.65. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The business had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same quarter in the prior year, the company posted $0.94 earnings per share. Teva Pharmaceutical Industries’s revenue was down 15.2% compared to the same quarter last year. Equities analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sol J. Barer acquired 111,000 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, June 3rd. The stock was acquired at an average price of $8.98 per share, with a total value of $996,780.00. Following the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The disclosure for this purchase can be found here. Insiders have sold 18,860 shares of company stock valued at $226,854 in the last quarter. 0.49% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Kore Private Wealth LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $29,000. Bruderman Asset Management LLC grew its stake in Teva Pharmaceutical Industries by 2,175.0% in the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after purchasing an additional 2,262 shares during the period. Coastal Investment Advisors Inc. bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $37,000. Lindbrook Capital LLC grew its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after purchasing an additional 945 shares during the period. Finally, Cullen Frost Bankers Inc. bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $40,000. Hedge funds and other institutional investors own 65.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/06/12/teva-pharmaceutical-industries-nyseteva-hits-new-12-month-low-at-8-25.html.

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What is a Futures Contract?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.